Долгая жизнь с муковисцидозом

216

Høiby N. Epidemiological investigations of the respiratory tract bacteriology in patients with cystic fibrosis. Acta Pathol Microbiol Scand В Microbiol Immunol 1974; 82: 541-50.

217

Spencer RC. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. J Hosp Infect 1995; 30(Suppl): 453-64.

218

Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23: 299–323.

219

Hauser AR, Jain M, Bar-Meir M, et al. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 2011; 24: 29–70.

220

Courtney JM, Bradley J, Mccaughan J, et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007; 42: 525-32.

221

Courtney JM, Dunbar KE, McDowell A, et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 2004; 3: 93-8.

222

Courtney JM, Dunbar KE, McDowell A, et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 2004; 3: 93-8.

223

Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984; 104: 206-10.

224

Tablan ОС, Martone WJ, Doershuk CF et al. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis.

225

Cystic Fibrosis Foundation. Patient registry annual data report 2012. Bethesda: Cystic Fibrosis Foundation; 2012. http://www.cff.org/UploadedFiles/research/Clinical Research/PatientRegistryReport/2012-CFF-Patient-Registry.pdf

226

European Cystic Fibrosis Society. ECFS patient registry. Annual data report 2010. Karup: European Cystic Fibrosis Society; 2010. https://www.ecfs.eu/files/webfm/webfiles/File/ecfs_registry/ECFSPR_Report10_v12014_final_020617.pdf

227

Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23: 299–323.

228

Vandamme P, Holmes B, Vancanneyt M, et al. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacterid 1997; 47: 1188-200.

229

Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23: 299–323.

230

Holmes A, Nolan R, Taylor R, et al. An epidemic of Burkholderia cepacia transmitted between patients with and without cystic fibrosis. J Infect Dis 1999; 179: 1197-205.

231

Sun L, Jiang RZ, Steinbach S, et al. The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat Med 1995; 1: 661-6.

232

Saiman L, Siegel JD, LiPuma JJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014; 35 (Suppl 1):S1-S67.

233

Savant AP, O'Malley C, Bichl S, et al. Improved patient safety through reduced airway infection rates in a paediatric cystic fibrosis programme after a quality improvement effort to enhance infection prevention and control measures. BMJ Quality Safety 2014;23(Suppl1):i73-i80.

234

Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008; 8: 1025-30.

235

Murray S, Charbeneau J, Marshall ВС, et al. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J RespirCrit Care Med 2008; 178: 363-71.

236

Gilchrist FJ, Webb AK, Bright-Thomas RJ, et al. Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids. J Cyst Fibros 2012; 11:458-60.

237

Uluer AZ, Waltz DA, Kalish LA, et al. Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis. J Cyst Fibros 2013; 12:54-9.

238

Tullis DE, Burns JL, Retsch-Bogart GZ, et al. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J Cyst Fibros 2014; 13: 296–305.

239

Horsley A, Jones AM. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. Cochrane Database Syst Rev 2012; 10: CD009529.

240

Cystic Fibrosis Foundation. Patient registry annual data report 2012. Bethesda: Cystic Fibrosis Foundation; 2012. http://www.cff.org/UploadedFiles/research/Clinical Research/PatientRegistryReport/2012-CFF-Patient-Registry.pdf

241

Emerson J, McNamara S, Buccat AM, et al. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008, Pediatr Pulmonol 2010; 45: 363-70.

242

Ridderberg W, Bendstrup KE, Olesen HV, et al. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J Cyst Fibros 2011; 10:466-9.

243

Hansen CR, Pressler T, Ridderberg W, et al. Achromobacter species in cystic fibrosis: crossinfection caused by indirect patient-to-patient contact. J Cyst Fibros 2013; 12:609-15.

244

Ronne Hansen C, Pressler T, H0iby N, et al. Chronic infection with Achromobacter xylosoxidans'm cystic fibrosis patients; a retrospective case control study. J Cyst Fibros 2006; 5: 245-51.

245

Amoureux L, Bador J, Siebor E, et al. Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data. J Cyst Fibros 2013; 12: 170-6.

246

Jakobsen TH, Hansen MA, Jensen P0, et al. Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypes. PLoS One 2013; 8: e68484.

247

Raso T, Bianco O, Grosso B, et al. Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients. APMIS 2008; 116: 837-11.

248

Moissenet D, Baculard A, Valcin M, et al. Colonization by Alcaligenes xylosoxidans in children with cystic fibrosis: a retrospective clinical study conducted by means of molecular epidemiological investigation. Clin Infect Dis 1997; 24: 274-5.

249

Kanellopoulou M, Pournaras S, Iglezos H, et al. Persistent colonization of nine cystic fibrosis patients with an Achromobacter (Alcaligenes) xylosoxidans clone. Eur J Clin Microbiol Infect Dis 2004; 23: 336-9.

250

Hansen C, Pressler T, H0ibyN,et al. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. J Cyst Fibros 2006;5:245-51.

251

Magni A, Trancassmi M, Varesi P, et al. Achromobacter xylosoxidans genomic characterization and correlation of randomly amplified polymorphic DNA profiles with relevant clinical features [corrected] of cystic fibrosis patients. J Clin Microbiol 2010; 48:1035-9.

252

Trancassini M, lebba V, Citera N, et al. Outbreak of Achromobarter xylosoxidans'm an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains. Front Microbiol 2014; 5: 138.

253

Magni A, Trancassmi M, Varesi P, et al. Achromobacter xylosoxidans genomic characterization and correlation of randomly amplified polymorphic DNA profiles with relevant clinical features [corrected] of cystic fibrosis patients. J Clin Microbiol 2010; 48:1035-9.

254

European Cystic Fibrosis Society. ECFS patient registry. Annual data report 2010. Karup: European Cystic Fibrosis Society; 2010. https://www.ecfs.eu/files/webfm/webfiles/File/ecfs_registry/ECFSPR_Report10_v12014_final_020617.pdf

255

Coenye T Falsen E, Hoste B, et al. Description of Pandoraeagen. nov. with Pandoraea apista sp. nov., Pandoraea pulmonicola sp. nov., Pandoraea pnomenusa sp. nov., Pandoraea sputorum sp. nov. and Pandoraea norimbergensiscomb. nov. Int J Syst Evol Microbiol 2000; 50(Pt 2): 887-99.

256

Atkinson RM, LipumaJJ, Rosenbluth DB, et al. Chronic colonization with Pandoraea apista in cystic fibrosis patients determined by repetitive-element-sequence PCR. J Clin Microbiol 2006; 44: 833-6.

257

Costello A, Herbert G, Fabunmi L, et al. Virulence of an emerging respiratory pathogen, genus Pandoraea, in vivo and its interactions with lung epithelial cells. J Med Microbiol 2011; 60(Pt 3): 289-99.

258

Jorgensen IM, Johansen HK, Frederiksen B, et al. Epidemic spread of Pandoraea apista,a new pathogen causing severe lung disease in cystic fibrosis patients. Pediatr Pulmonol 2003; 36: 439-16.

259

Coenye T, Goris J, Spilker T, et al. Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of Inquilinus limosusgen. nov, sp. nov, J Clin Microbiol 2002; 40: 2062-9.

260

Bittar F, Richet H, Dubus JC, et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 2008; 3:e2908.

261

Bittar F, Richet H, Dubus JC, et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 2008; 3:e2908.

262

Bittar F, Leydier A, Bosdure E, et al. Inquilinus limosus and cystic fibrosis. Emerg Infect Dis 2008; 14:993-5.

263

Bittar F, Richet H, Dubus JC, et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 2008; 3:e2908.

264

Høiby N., Ciofu O, Johansen HK, et al. The clinical impact of bacterial bio-films, Int J Oral Sci 2011; 3: 55–65.

265

Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109:317-25.

266

Su S, Hassett DJ. Anaerobic Pseudomonas aeruginosa and other obligated anaerobic bacterial biofilms growing in the thick airway mucus of chronically infected cystic fibrosis patients: an emerging paradigm or "Old Hat"? Expert Opin Ther Targets 2012; 16:859-73.

267

Giliigan PH. Infections in patients with cystic fibrosis: diagnostic microbiology update. Clin Lab Med 2014; 34: 197–217.

268

Zemanick ET, Harris JK, Wagner BD, et al. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoSOne2013;8:e62917

269

Zemanick ET, Harris JK, Wagner BD, et al. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoSOne2013;8:e62917

270

Jones AM. Anaerobic bacteria in cystic fibrosis: pathogens or harmless commensals? Thorax 2011;66:558-9.

271

Zemanick ET, Sagel SD, Harris JK. The airway microbiome in cystic fibrosis and implications for treatment. Curr Opin Pediatr 2011;23:319-24.

272

Smith AL, Fiel SB, Mayer-Hamblett N, et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003; 123: 1495-502.

273

Bryant JM,Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013; 381: 1551-60.

274

Esther CR Jr, Esserman DA, Gilligan R et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9: 117-23.

275

Seddon R Fidler K, Raman S, et al. Prevalence of nontuberculous mycobacteria in cystic fibrosis clinics, United Kingdom, 2009. Emerg Infect Dis 2013; 19: 1128-30.

276

Roux A-L, Catherinot E, Ripoll F, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol 2009; 47: 4124-8.

277

Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/ IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367–416.

278

Esther CR Jr, Esserman DA, Gilligan R et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9: 117-23.

279

Esther CR Jr, Esserman DA, Gilligan R et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9: 117-23.

280

Esther CR Jr, Esserman DA, Gilligan R et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9: 117-23.

281

Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/ IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367–416.

282

Catherinot E, Roux A-L, Vibet M-A, et al. Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients. Eur Respir J 2013; 41: 1101-6.

283

Mussaffi H, Rivlin J, Shalit I, et al. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J 2005; 25: 324-8.

284

Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011; 121:3554-63.

285

Catherinot E, Roux A-L, Vibet M-A, et al. Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients. Eur Respir J 2013; 41: 1101-6.

286

Binder AM, Adjemian J, Olivier KN, et al. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013; 188: 807-12.

287

Binder AM, Adjemian J, Olivier KN, et al. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013; 188: 807-12.

288

Leung JM, Olivier KN. Nontuberculous mycobacteria in patients with cystic fibrosis. Semin Respir Crit Care Med 2013; 34: 124-34.

289

Leung JM, Olivier KN. Nontuberculous mycobacteria in patients with cystic fibrosis. Semin Respir Crit Care Med 2013; 34: 124-34.

290

Lobo LJ, Chang LC, Esther CR, et al. Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections. Clin Transplant 2013; 27: 523-9.

291

Chotirmall SH, McElvaney NG. Fungi in the cystic fibrosis lung: bystanders or pathogens? Int J Biochem Cell Biol 2014; 52: 161-73.

292

Pihet M, Carrere J, Cimon B, et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis – a review. Med Mycol 2009; 47: 387-97

293

Le Bourgeois M, Sermet I, Bailly-Botuha C, et al. [Fungal infections in cystic fibrosis]. Arch Pediatr 2011; 18(Suppl1):S15-21.

294

Muller FM, Seidler M. Characteristics of pathogenic fungi and antifungal therapy in cystic fibrosis. Expert Rev Anti Infect Ther 2010; 8: 957-64.

295

Nielsen SM, Kristensen L, S0ndergaard A, et al. Increased prevalence and altered species composition of filamentous fungi in respiratory specimens from cystic fibrosis patients. APMIS 2014; 122: 1007-12.

296

Skov M. Aspergillus fumigatus lung colonization and infection in patients with cystic fibrosis. PhD thesis. University of Copenhagen, Denmark. 2001.

297

Shoseyov D, Brownlee KG, Conway SR et al. Aspergillus bronchitis in cystic fibrosis. Chest 2006; 130: 222-6.

298

Jones AM, Horsley A, Denning DW. What is the importance of classifying Aspergillus disease in cystic fibrosis patients? Expert Rev Respir Med 2014; 8: 389-92.

299

Shoseyov D, Brownlee KG, Conway SR et al. Aspergillus bronchitis in cystic fibrosis. Chest 2006; 130: 222-6.

300

Stevens DA, Moss RB, Kurup VR et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis – state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37(Suppl 3): S225-64.

301

Shoseyov D, Brownlee KG, Conway SR et al. Aspergillus bronchitis in cystic fibrosis. Chest 2006; 130: 222-6.

302

Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoal-veolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008; 177:27–34.

303

Desai R, Ross LA, Hoffman JA. The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis. Pediatr Infect Dis J 2009; 28: 283-6.

304

Denning DW. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001; 7(Suppl 2): 25–31.

305

Kroner C, Kappler M, Grimmelt AC, et al. The basidiomycetous yeast Trlchosporon may cause severe lung exacerbation in cystic fibrosis patients – clinical analysis of Trlchosporon positive patients in a Munich cohort. BMC Pulm Med 2013; 13:61.

306

Kondori N, Lindblad A, Welinder-Olsson C, et al. Development of IgG antibodies to Exophiala dermatltldls is associated with inflammatory responses in patients with cystic fibrosis. J Cyst Fibros 2014; 13:391-9.

307

Parize P Billaud S, Bienvenu AL, et al. Impact of Scedosporium aplospermum complex seroprevalence in patients with cystic fibrosis. J Cyst Fibros 2014; 13: 667-73.

308

Holle J, Leichsenring M, Meissner PE. Nebulized voriconazole in infections with Scedosporium aplospermum – case report and review of the literature. J Cyst Fibros 2014; 13:400–402.

309

Russell GK, Gadhok R, Simmonds NJ. The destructive combination of Scediosporium apiosperum [sic] lung disease and exuberant inflammation in cystic fibrosis. Paediatr Respir Rev 2013; 14(Suppl 1): 22–25.

310

Muller FM, Seidler M. Characteristics of pathogenic fungi and antifungal therapy in cystic fibrosis. Expert Rev Anti Infect Ther 2010; 8: 957-64.

311

Chotirmall SH, Greene CM, McEIvaney NG. Candida species in cystic fibrosis: a road less travelled. Med Mycol 2010; 48(Suppl 1): S114-24.

312

Baxter CG, Moore CB, Jones AM, et al. IgE-mediated immune responses and airway detection of Aspergillus and Candida in adult cystic fibrosis. Chest 2013; 143: 1351-7.

313

Chamnan R Shine BS, Haworth CS, et al. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care 2010; 33: 311-16.

314

Moran A, Dunitz J, Nathan B, et al. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009; 32: 1626-31.

315

van den Berg JM, Kouwenberg JM, Heijerman HG. Demographics of glucose metabolism in cystic fibrosis. J Cyst Fibros 2009; 8: 276-9.

316

Lanng S, Hansen A, Thorsteinsson B, et al. Glucose tolerance in patients with cystic fibrosis: five year prospective study. BMJ 1995;311:655-9.

317

AdlerAI, Gunn E, Haworth CS, et al. Characteristics of adults with and without cystic fibrosis-related diabetes. Diabet Med 2007; 24: 1143-8.

318

Adler Al, Shine BS, Chamnan P, et al. Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults. Diabetes Care 2008; 31: 1789-94.

319

Adler Al, Shine BS, Chamnan P, et al. Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults. Diabetes Care 2008; 31: 1789-94.

320

Marshall ВС, Butler SM, Stoddard M, et al. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005; 146: 681-7.

321

KochC, RainisioM, Madessani U, et al. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 2001; 32: 343-50.

322

Moran A, Doherty L, Wang X, et al. Abnormal glucose metabolism in cystic fibrosis. J Pediatr 1998; 133: 10–17.

323

Huang CJ, Lin CY, Haataja L, et al. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 2007; 56: 2016-27

324

Minicucci L, Cotellessa M, Pittaluga L, et al. Beta-cell autoantibodies and diabetes mellitus family history in cystic fibrosis. J Pediatr Endocrinol Metab 2005; 18: 755-60.

325

Lanng S, Thorsteinsson B, Pociot F, et al. Diabetes mellitus in cystic fibrosis: genetic and immunological markers. Acta Paediatr 1993; 82: 150-4.

326

Lombardo F, De Luca F, Rosano M, et al. Natural history of glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic fibrosis patients with fasting euglycemia. Eur J Endocrinol 2003; 149: 53-9.

327

Street ME, Spaggian C, Ziveri MA, et al. Insulin production and resistance in cystic fibrosis: effect of age, disease activity, and genotype. J Endocrinol Invest 2012; 35: 246-53.

328

Battezzati A, Mari A, Zazzeron L, et al. Identification of insulin secretory defects and insulin resistance during oral glucose tolerance test in a cohort of cystic fibrosis patients. Eur J Endocrinol 2011; 165:69–76.

329

Mohan V, Alagappan V, Snehalatha C, et al. Insulin and C-peptide responses to glucose load in cystic fibrosis. Diabete Metab 1985; 11:376-9.

330

Moran A, Diem P, Klein DJ, et al. Pancreatic endocrine function in cystic fibrosis. J Pediatr 1991; 118:715-23.

331

Bellin MD, Laguna T, Leschyshyn J, et al. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes 2013; 14:417-21.

332

Perano SJ, Couper JJ, Horowitz M, et al. Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycaemia in adolescents with cystic fibrosis: a randomized crossover trial. J Clin Endocrinol Metab 2014; 99: 2486-93

333

Moran A, Pyzdrowski KL, Weinreb J, et al. Insulin sensitivity in cystic fibrosis. Diabetes 1994; 43: 1020-6.

334

Kastner-Cole D, Palmer CN, Ogston SA, et al. Overweight and obesity in deltaF508 homozygous cystic fibrosis. J Pediatr 2005; 147: 402-1.